EVALUATING AND REPORTING DYSPHAGIA IN TRIALS OF CHEMOIRRADIATION FOR HEAD-AND-NECK CANCER

被引:29
作者
Gluck, Iris [1 ]
Feng, Felix Y. [1 ]
Lyden, Teresa [2 ]
Haxer, Marc [2 ]
Worden, Francis [3 ]
Chepeha, Douglas B. [4 ]
Eisbruch, Avraham [1 ]
机构
[1] Univ Michigan, Dept Radiat Oncol, Ann Arbor, MI 48109 USA
[2] Univ Michigan, Dept Speech Pathol, Ann Arbor, MI 48109 USA
[3] Univ Michigan, Dept Med, Ann Arbor, MI 48109 USA
[4] Univ Michigan, Dept Otolaryngol Head Neck Surg, Ann Arbor, MI 48109 USA
来源
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2010年 / 77卷 / 03期
关键词
Dysphagia; Swallowing; Head-and-neck cancer; Chemoirradiation; Quality of life; CTCAE v3; QUALITY-OF-LIFE; PHASE-II TRIAL; SQUAMOUS-CELL CARCINOMA; LOCALLY ADVANCED HEAD; THERAPY-ONCOLOGY-GROUP; INTENSITY-MODULATED RADIOTHERAPY; ACCELERATED RADIATION-THERAPY; PROSPECTIVE RANDOMIZED-TRIAL; CONCOMITANT BOOST RADIATION; ORGAN PRESERVATION;
D O I
10.1016/j.ijrobp.2009.05.049
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Reporting long-term toxicities in trials of chemoirradiation (CRT) of head-and-neck cancer (HNC) has mostly been limited to observer-rated maximal Grades >= 3. We evaluated this reporting approach for dysphagia by assessing patient-reported dysphagia (PRD) and objective swallowing dysfunction through videofluoroscopy (VF) in patients with various grades of maximal observer-reported dysphagia (ORD). Methods and Materials: A total of 62 HNC patients completed quality-of-life questionnaires periodically through 12 months post-CRT. Five PRD items were selected: three dysphagia-specific questions, an Eating-Domain, and "Overall Bother." They underwent VF at 3 and 12 months, and ORD (Common Terminology Criteria for Adverse Events) scoring every 2 months. We classified patients into four groups (0-3) according to maximal ORD scores documented 3-12 months post-CRT, and assessed PRD and VF summary scores in each group. Results: Differences in ORD scores among the groups were considerable throughout the observation period. In contrast, PRD scores were similar between Groups 2 and 3, and variable in Group 1. VF scores were worse in Group 3 compared with 2 at 3 months but similar at 12 months. In Group 1, PRD and VF scores from 3 through 12 months were close to Groups 2 and 3 if ORD score 1 persisted, but were similar to Group 0 in patients whose ORD scores improved by 12 months. Conclusions: Patients with lower maximal ORD grades, especially if persistent, had similar rates of PRD and objective dysphagia as patients with highest grades. Lower ORD grades should therefore be reported. These findings may have implications for reporting additional toxicities besides dysphagia. (C) 2010 Elsevier Inc.
引用
收藏
页码:727 / 733
页数:7
相关论文
共 52 条
[1]   Intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer [J].
Adelstein, DJ ;
Li, Y ;
Adams, GL ;
Wagner, H ;
Kish, JA ;
Ensley, JF ;
Schuller, DE ;
Forastiere, AA .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (01) :92-98
[2]   Some thoughts on the reporting of adverse events in phase II cancer clinical trials [J].
Anderson, Stewart J. .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (24) :3821-3822
[3]   Concomitant boost radiation plus concurrent cisplatin for advanced head and neck carcinomas: Radiation therapy oncology group phase II trial 99-14 [J].
Ang, KK ;
Harris, J ;
Garden, AS ;
Trotti, A ;
Jones, CU ;
Carrascosa, L ;
Cheng, JD ;
Spencer, SS ;
Forastiere, A ;
Weber, RS .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (13) :3008-3015
[4]   Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: results of a questionnaire-based study [J].
Basch, Ethan ;
Iasonos, Alexia ;
McDonough, Tiffani ;
Barz, Allison ;
Culkin, Ann ;
Kris, Mark G. ;
Scher, Howard I. ;
Schrag, Deborah .
LANCET ONCOLOGY, 2006, 7 (11) :903-909
[5]   Evaluation of early and late Toxicities in chemoradiation trials [J].
Bentzen, Soren M. ;
Trotti, Andrea .
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (26) :4096-4103
[6]   Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer [J].
Bernier, J ;
Domenge, C ;
Ozsahin, M ;
Matuszewska, K ;
Lefèbvre, JL ;
Greiner, RH ;
Giralt, J ;
Maingon, P ;
Rolland, F ;
Bolla, M ;
Cognetti, F ;
Bourhis, J ;
Kirkpatrick, A ;
van Glabbeke, M .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (19) :1945-1952
[7]   Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck [J].
Bonner, JA ;
Harari, PM ;
Giralt, J ;
Azarnia, N ;
Shin, DM ;
Cohen, RB ;
Jones, CU ;
Sur, R ;
Raben, D ;
Jassem, J ;
Ove, R ;
Kies, MS ;
Baselga, J ;
Youssoufian, H ;
Amellal, N ;
Rowinsky, EK ;
Ang, KK .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (06) :567-578
[8]   Phase III randomized trial of very accelerated radiation therapy compared with conventional radiation therapy in squamous cell head and neck cancer: A GORTEC trial [J].
Bourhis, Jean ;
Lapeyre, Michel ;
Tortochaux, Jacques ;
Rives, Michel ;
Aghili, Mehdi ;
Bourdin, Sylvain ;
Lesaunier, Francois ;
Benassi, Toufik ;
Lemanski, Claire ;
Geoffrois, Lionel ;
Lusinchi, Antoine ;
Verrelle, Pierre ;
Bardet, Etienne ;
Julieron, Morbize ;
Wibault, Pierre ;
Luboinski, Monique ;
Benhamou, Ellen .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) :2873-2878
[9]   Hyperfractionated accelerated chemoradiation with concurrent fluorouracil-mitomycin is more effective than dose-escalated hyperfractionated accelerated radiation therapy alone in locally advanced head and neck cancer: Final results of the radiotherapy cooperative clinical trials group of the German cancer society 95-06 prospective randomized trial [J].
Budach, V ;
Stuschke, M ;
Budach, W ;
Baumann, M ;
Geismar, D ;
Grabenbauer, G ;
Lammert, I ;
Jahnke, K ;
Stueben, G ;
Herrmann, T ;
Bamberg, M ;
Wust, P ;
Hinkelbein, W ;
Wernecke, KD .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (06) :1125-1135
[10]   Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma [J].
Calais, G ;
Alfonsi, M ;
Bardet, E ;
Sire, C ;
Germain, T ;
Bergerot, P ;
Rhein, B ;
Tortochaux, J ;
Oudinot, P ;
Bertrand, P .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1999, 91 (24) :2081-2086